Cryogenic logistics company, Cryoport, Inc., has launched extra service offerings as a result of increased demand for added cryogenic storage and fulfilment capabilities.
The first of the US-based enterprise’s new business units, Cryoport Biostorage, will store and transport all temperature-sensitive biologic material including vaccines, stem cells and regenerative therapies.
Additionally, Cryoport has formally launched its Laboratory Relocation Service – literally a service that transports entire laboratories – which will manage a secure transportation of lab materials, equipment and instruments. Cryoport has already carried out lab moves for Fred Hutchinson Cancer Research Centres’ Clinical Research Division and Smithsonian.
These expanded capabilities are building upon our position as the partner-of-choice when it comes to temperature-controlled solutions
Jerrell Shelton, CEO, explained, “Our entry into the bio-storage market in particular is an important step in realising our vision to deliver fully integrated solutions that further enhances the biopharma industry’s ability to safely and efficiently manage their most valuable biological assets.”
“Cryoport is continuing to add new, strategic, lines of business solutions, including expert consulting, bio-storage and laboratory relocation services. These expanded capabilities are building upon our position as the partner-of-choice when it comes to temperature-controlled solutions and most important, fill a clear void in the global market for a fully-integrated, fully-compliant solution from a single-source provider.”